학술논문

72O - Addition of durvalumab (Dur) upon progression to bevacizumab (Bev) maintenance in advanced HER2-negative (HERNEG) breast cancer (BC): Safety, efficacy and biomarkers
Document Type
Abstract
Source
In Annals of Oncology November 2018 29 Supplement 9:ix24-ix24
Subject
Language
ISSN
0923-7534